Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is tackling three persistent problems in cancer drug development—tumor resistance, high clinical trial failure rates, and drug toxicity—by combining a novel biological target, advanced drug delivery, and artificial intelligence into a unified strategy. The company's lead candidate, ONC010, pairs a PNKP inhibitor—a DNA Damage Response (DDR) target distinct from PARP—with a nanoparticle delivery system, while leveraging AI through its Inka Health subsidiary and the SynoGraph causal AI platform.
Cancer treatments such as radiation and chemotherapy work by damaging tumor DNA, but cancer cells can survive by repairing that damage. DDR inhibitors have become a rapidly advancing category in oncology, with PARP inhibitors leading the way. Onco-Innovations focuses on PNKP, a newer target that may offer advantages in certain tumor types. The company is advancing ONC010 through IND-enabling studies, manufacturing, and regulatory work, while using AI-enabled tools to support patient stratification, trial design, and evidence generation.
The integration of these three frontiers—novel biology, nanoparticle delivery, and AI—positions Onco-Innovations to potentially address some of oncology's most persistent development challenges. By using AI to identify the right patients for clinical trials, the company aims to reduce the high costs and failure rates associated with traditional trial designs. The nanoparticle delivery system is intended to improve drug targeting and reduce toxicity, potentially enabling more effective treatments with fewer side effects.
For more information, visit the company's newsroom at ibn.fm/ONNVF. This press release is disseminated on behalf of Onco-Innovations Limited and may include paid advertising.
